[Jackie07]

About Parp trial:

There are whole bunch of them available according to the PubMed database:
http://clinicaltrials.gov/ct2/results?term=PARP

Below is one of them:

PARP Inhibitor for Triple Negative or BRCA1/2 Breast Cancer

Show again
Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer (7161)
Summary

Researchers are trying to develop new therapies for triple negative and BRCA-positive breast cancer. Chemotherapy drugs, such as cisplatin (Platinol®) and vinorelbine ditartrate (Navelbine®), work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. ABT-888 (veliparib) is a poly(ADP-ribose) polymerase (PARP) inhibitor. It may stop the growth of some tumors cells by blocking some of the enzymes involved in DNA repair that are needed for cell growth. Studies suggest that giving ABT-888 together with combination chemotherapy may be more effective than chemotherapy alone. This trial is studying the side effects and best dose of ABT-888 when given together with cisplatin and vinorelbine ditartrate in treating individuals with recurrent and/or metastatic breast cancer.
This is a Phase I trial
What's involved:



All participants will receive the following during each 21-day cycle:

• ABT-888 (veliparib) by mouth twice daily on days 1-14

• Cisplatin (Platinol®) by IV on day 1

• Vinorelbine ditartrate (Navelbine®) by IV on days 1 and 8

Treatment repeats every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity.
Note: Treatment with ABT-888 alone may continue in the absence of disease progression or unacceptable toxicity.

Additional procedures:

Please contact research site
Trial length:

4-7 months
Post-trial follow-up:

Up to 30 days
Sponsor:

Other
More information

NCI listing including eligibility criteria and contact information: Cancer.gov (PDQ®) [Aug 2, 2010]